synergy nash tirzepatide Tirzepatide: A Game-Changer for MASH Treatment SURPASS to SURMOUNT: The Tirzepatide

Last year, Edisons team shared data from the first clinical trial showing that a GLP-1 drug can slow Alzheimers disease progression

The landmark SURMOUNT-5 phase 3 trial compared tirzepatide and semaglutide head-to-head over 72 weeks in people with obesity

However, the FDA-approved labeling for Zepbound does include a general warning that it may affect the absorption of any oral medication

The significant difference is that Ozempic is approved to address insulin resistance for those with Type 2 Diabetes and not for weight loss, whereas Wegovy is approved as a weight loss treatment for those who qualify

When bound in prodrug form, the carrier inactivates the parent drug and shields it from receptor uptake, renal clearance, and enzymatic degradation

Semaglutide remains a strong and effective option